DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of agilon health
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 17 2024
0mins
Should l Buy AGL?
Source: PRnewswire
- Investigation by Faruqi & Faruqi, LLP: The law firm is investigating potential claims against agilon health, inc. and reminds investors of the May 20, 2024 deadline to seek the role of lead plaintiff in a federal securities class action.
- Allegations Against Agilon: The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements about medical costs, business model effectiveness, financial guidance, and risk disclosures.
- Revelation of Higher Medical Costs: Agilon faced increased medical costs which were revealed on November 2, 2023, leading to a stock price drop. Further surprises in January 2024 included lowered profit forecasts and the CFO's retirement announcement.
- Lead Plaintiff Role: The court-appointed lead plaintiff oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff or remain an absent class member.
- Encouragement for Information Sharing: Faruqi & Faruqi, LLP encourages anyone with information regarding agilon's conduct to contact the firm, including whistleblowers, former employees, shareholders, and others.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AGL
Wall Street analysts forecast AGL stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.354
Low
0.88
Averages
0.88
High
0.88
Current: 0.354
Low
0.88
Averages
0.88
High
0.88
About AGL
agilon health, inc. is a healthcare company. It enables primary care physicians (PCP) to be the agents for change in the communities they serve. Through its combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, it offers healthcare for seniors across communities throughout the United States. Its model operates by primarily forming risk-bearing entities (RBEs) within local geographies, that enter into arrangements with payors providing for monthly payments to manage the total healthcare needs of its physician partners’ attributed patients (or global capitation arrangements). It focuses on community-based physician groups and is built around three key elements: agilon’s platform, agilon’s long-term physician partnership approach, and agilon’s network. The agilon platform is holistic in supporting the rapid transition to a Total Care Model with technology, people, process and capital.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Class Action Overview: The Law Offices of Frank R. Cruz remind investors that class action lawsuits have been filed against companies including agilon health, Fermi Inc., Varonis Systems, and Ardent Health, with deadlines for lead plaintiff motions approaching.
- agilon health Allegations: From February 26 to August 4, 2025, agilon health is accused of making materially false statements regarding its financial guidance, failing to disclose industry headwinds, which misled investors about the company's prospects, with a lead plaintiff deadline of March 2, 2026.
- Fermi Inc. Lawsuit Details: Fermi Inc. is charged with overstating tenant demand and the reliance on a single tenant's funding for its Project Matador from October 1 to December 11, 2025, with a lead plaintiff deadline of March 6, 2026.
- Varonis and Ardent Issues: Varonis is accused of being ill-equipped to sustain its ARR growth from February 4 to October 28, 2025, while Ardent is charged with failing to accurately assess the collectability of accounts receivable from July 18, 2024, to November 12, 2025, with lead plaintiff deadlines of March 9, 2026, for both companies.
See More
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Agilon Health, Inc. on behalf of investors who purchased securities between February 26, 2025, and August 4, 2025, alleging that the company made false and misleading statements during this period, resulting in investor losses.
- Allegation Details: The lawsuit claims that Agilon executives issued unrealistic 2025 financial guidance despite being aware of significant industry challenges, and materially overstated the positive financial impact of their strategic actions, leading to a severely distorted view of the company's business and prospects among investors.
- Investor Rights: Affected investors must apply by March 2, 2026, to be appointed as lead plaintiffs in the lawsuit to protect their legal rights, with Bragar Eagel & Squire offering free consultations and encouraging investors to reach out for more information.
- Law Firm Overview: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in representing individual and institutional investors in securities, derivative, and commercial litigation, boasting extensive litigation experience and a nationwide practice.
See More
- Class Action Initiated: Robbins LLP reminds shareholders that a class action has been filed on behalf of investors who purchased Agilon Health (NYSE: AGL) securities between February 26, 2025, and August 4, 2025, alleging the company failed to disclose significant risks to its business prospects.
- Misleading Financial Guidance: The complaint alleges that Agilon Health issued optimistic financial guidance for 2025 despite being aware of substantial industry headwinds, misleading investors and overstating the positive impact of strategic actions taken to mitigate risks.
- Executive Departure Impact: On August 4, 2025, Agilon announced the resignation of CEO Steven Sell, and the subsequent disappointing financial results led to a stock price drop of over 50% to close at $0.8801 on August 5, 2025, significantly impacting investor confidence.
- Call to Action for Shareholders: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by March 2, 2026, while those who choose not to participate can remain absent class members and still retain their rights to recovery.
See More
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Agilon Health, alleging violations of federal securities laws on behalf of all investors who purchased Agilon securities between February 26, 2025, and August 4, 2025.
- False Statement Allegations: The complaint claims that Agilon executives issued unrealistic 2026 financial guidance despite being aware of significant industry headwinds, while also overstating the immediate financial benefits of strategic actions taken, misleading investors throughout the class period.
- Investor Actions: Affected investors are encouraged to apply to be lead plaintiffs by March 2, 2026, to share in any potential recovery from the lawsuit, with the option to participate without being the lead plaintiff.
- Law Firm's Advantage: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions, having recovered hundreds of millions for investors, emphasizing their commitment to restoring investor capital and ensuring corporate accountability.
See More
- Leadership Change: Agilon Health announced on August 4, 2025, that CEO Steven Sell stepped down, raising concerns about the company's future and leading to a decline in investor confidence.
- Guidance Withdrawal: Concurrently with the leadership transition, Agilon Health withdrew its full-year 2025 earnings guidance, indicating uncertainty about future performance, which may affect investor decision-making.
- Stock Price Plunge: Following the announcement, Agilon Health's shares fell over 27% in after-hours trading, reflecting a pessimistic outlook from the market and potentially prompting more investors to seek legal recourse.
- Legal Investigation Initiated: DJS Law Group is investigating whether Agilon Health made misleading statements or failed to disclose critical information, aiming to protect investor rights and pursue potential compensation.
See More
- Class Action Notice: Rosen Law Firm reminds investors who purchased Agilon Health (NYSE:AGL) securities between February 26 and August 4, 2025, that they must apply to be lead plaintiff by March 2, 2026, or risk losing the opportunity to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, allowing investors to seek compensation without financial burden, thereby lowering the barrier to litigation participation.
- Lawsuit Background: The lawsuit alleges that Agilon Health made misleading financial guidance during the class period, resulting in investor losses when the true details emerged, indicating that the company failed to accurately reflect its financial health amidst industry challenges, which could impact future market trust.
- Law Firm Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling similar cases, which investors should consider when selecting legal counsel.
See More








